Condition: Locally Advanced or Metastatic Solid Tumors · Esophageal Squamous Cell Cancer · Head and Neck Squamous Cell Cancer · Sponsor: Exelixis
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.
This description comes directly from the study's public registry record.
Exelixis Clinical Trials · 1-888-EXELIXIS (888-393-5494) · druginfo@exelixis.com
Backup or International · 650-837-7400
Always discuss trial participation with your own doctor first.
| City of Hope Orange County Lennar Foundation Cancer Center | Irvine, California, United States | Recruiting |
| UCLA Department of Medicine - Hematology/Oncology | Los Angeles, California, United States | Recruiting |
| Georgetown University Medical Center | Washington D.C., District of Columbia, United States | Recruiting |
| Sarah Cannon Research Institute at Florida Cancer Specialists | Orlando, Florida, United States | Recruiting |
| Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| University of Chicago Medical Center | Chicago, Illinois, United States | Recruiting |
| Siteman Cancer Center | St Louis, Missouri, United States | Recruiting |
| Montefiore Medical Center - Montefiore Medical Park | The Bronx, New York, United States | Recruiting |
| Carolina BioOncology Institute | Huntersville, North Carolina, United States | Recruiting |
| Stephenson Cancer Center | Oklahoma City, Oklahoma, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| NEXT Austin | Austin, Texas, United States | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06545331